| Adamas Pharmaceuticals focuses on time-dependent biology to redefine the treatment for patients suffering from chronic neurological diseases. Co.'s approved product includes GOCOVRITM (amantadine) extended release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Co. is also advancing its pipeline of differentiated investigational programs, which includes ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified-release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. We show 21 historical shares outstanding datapoints in our coverage of ADMS's shares outstanding history.|
Understanding the changing numbers of ADMS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADMS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADMS by allowing them to research ADMS shares outstanding history
as well as any other stock in our coverage universe.